[Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
作者： L. Guilleminault , D. Carmier , N. Heuzé-Vourc’h , P. Diot , E. Pichon
DOI: 10.1016/J.PNEUMO.2014.11.004
关键词:
摘要: Despite recent advances in targeted therapy of non-small cell lung cancer (NSCLC), many patients do not benefit from these therapies. Inhibition PD1/PDL1 is an interesting therapeutic target which restores the immune system against tumor cells. PD1 located on lymphocytes and PDL1 antigen presenting are co-inhibition molecules their interaction results tolerance Anti-PD1 anti-PDL1 antibodies have been developed to restore solid including NSCLC. In phase I, studies assessing nivolumab, anti-PD1 antibody, objective responses were observed 13 18% NSCLC failing previous treatment. The data obtained with similar ranging 6 22%. encouraging I/II must be confirmed ongoing III studies. exposed new adverse events auto-immune diseases whose support codified. Questions about treatment duration criteria evaluation resolved. These treatments pave way for immunomodulation
elsevier.com
sci-hub.se 参考文章(83)
Y. Ishida, Y. Agata, K. Shibahara, T. Honjo, Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. The EMBO Journal. ,vol. 11, pp. 3887- 3895 ,(1992) , 10.1002/J.1460-2075.1992.TB05481.X
Haidong Dong, Gefeng Zhu, Koji Tamada, Lieping Chen, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nature Medicine. ,vol. 5, pp. 1365- 1369 ,(1999) , 10.1038/70932
Emilio Barbera-Guillem, Kenneth F. May, Julie K. Nyhus, M. Bud Nelson, Promotion of Tumor Invasion by Cooperation of Granulocytes and Macrophages Activated by Anti-tumor Antibodies Neoplasia. ,vol. 1, pp. 453- 460 ,(1999) , 10.1038/SJ.NEO.7900054
Karin E. de Visser, Alexandra Eichten, Lisa M. Coussens, Paradoxical roles of the immune system during cancer development Nature Reviews Cancer. ,vol. 6, pp. 24- 37 ,(2006) , 10.1038/NRC1782
Cheng Chen, Xue-Guang Zhang, Chuan-Yong Mu, Jian-An Huang, Ying Chen, High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation Medical Oncology. ,vol. 28, pp. 682- 688 ,(2011) , 10.1007/S12032-010-9515-2
Jun Konishi, Koichi Yamazaki, Miyuki Azuma, Ichiro Kinoshita, Hirotoshi Dosaka-Akita, Masaharu Nishimura, B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression Clinical Cancer Research. ,vol. 10, pp. 5094- 5100 ,(2004) , 10.1158/1078-0432.CCR-04-0428
Frances A. Shepherd, Jean-Yves Douillard, George R. Blumenschein, Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. Journal of Thoracic Oncology. ,vol. 6, pp. 1763- 1773 ,(2011) , 10.1097/JTO.0B013E31822E28FC
A F Gazdar, Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. ,vol. 28, ,(2009) , 10.1038/ONC.2009.198
Julie R. Brahmer, Charles G. Drake, Ira Wollner, John D. Powderly, Joel Picus, William H. Sharfman, Elizabeth Stankevich, Alice Pons, Theresa M. Salay, Tracee L. McMiller, Marta M. Gilson, Changyu Wang, Mark Selby, Janis M. Taube, Robert Anders, Lieping Chen, Alan J. Korman, Drew M. Pardoll, Israel Lowy, Suzanne L. Topalian, Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Journal of Clinical Oncology. ,vol. 28, pp. 3167- 3175 ,(2010) , 10.1200/JCO.2009.26.7609
C. Leduc, Les avancées de l'immunothérapie dans les cancers bronchiques non à petites cellules Revue des Maladies Respiratoires Actualités. ,vol. 4, pp. 667- 672 ,(2012) , 10.1016/S1877-1203(12)70320-8